<DOC>
	<DOC>NCT00568815</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).</brief_summary>
	<brief_title>Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)</brief_title>
	<detailed_description>The salvage therapy in the patients with DLBCL is still controversial. The investigators conducted this study to evaluate the efficacy and tolerability of Rituximab combined with ESHAP in the patients with DLBCL. The patients enrolled were defined to be relapsed or refractory after the first-line chemotherapy like CHOP or other CHOP-like regimens.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age range 1870 years old Histological confirmed diffuse large B cell lymphoma ECOG performance status no more than 2 Life expectancy of more than 3 months Relapse or refractory after the firstline chemotherapy of DLBCL No evidence of bone marrow involvement Normal laboratory values: hemoglobin &gt; 8.0g/dl, neutrophil &gt; 1.5×109/L, platelet &gt; 80×109/L, serum creatine &lt; 1× upper limitation of normal(ULN), serum bilirubin &lt; 1× ULN, ALT and AST &lt; 1.5× ULN Pregnant or lactating women Serious uncontrolled diseases and intercurrent infection The evidence of CNS metastasis and bone marrow involvement History of other malignancies except cured basal cell carcinoma of skin and carcinoma insitu of uterine cervix History of allergic reaction/hypersensitivity to rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>Rituximab</keyword>
	<keyword>ESHAP</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Toxicity</keyword>
</DOC>